News
0
From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the most recent offer reach...
0
Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of Janus Kinase (JAK) inhibitors,...
0
Hans Bishop, CEO and Co-founder of Juno Therapeutics is to step down from his role now that his company has been acquired by Celgene in a $9...
0
n the latest step to ramp up this push towards exploring digital tech solutions to age-old pharma problems, Novartis has revealed that it has...
Features
Tony Green discusses the difficulty in pinning down his diagnosis of the irregular heart rhythm condition, until his use of AliveCor’s...
Featured Appointment
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, which...
Service Company News
Featured Event
@Pharmafocus
